Catheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: Initial clinical experience
- 12 July 2002
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 56 (4), 508-515
- https://doi.org/10.1002/ccd.10292
Abstract
The surgical closure of membranous ventricular septal defects (VSDs) is associated with morbidity and low mortality. Six patients with VSDs located in the membranous part of the ventricular septum underwent an attempt of catheter closure using a new device specifically designed for the membranous septum. Patients ranged in age from 3.5 to 19 years (median, 10.5 years) and in weight from 15 to 45 kg (median, 29 kg). One patient with associated pulmonary valve stenosis had shortness of breath. The median Qp/Qs ratio was 1.6 (range, 1.1–3) and the median left ventricle end-diastolic dimension (LVEDD) was 44 mm (range, 38–52 mm). The devices were deployed via the femoral vein using 7–8 Fr sheaths. There was immediate complete closure in all patients. One patient developed trivial aortic regurgitation. There were no other complications. The median fluoroscopy time was 15.5 min (range, 10.3–53.4 min). At 24 hr, all patients were doing well. The median LVEDD decreased to 38 mm (range, 34–47 mm). One patient continued to have trace aortic regurgitation. All patients were discharged home after 24 hr. Transcatheter occlusion of membranous VSDs is safe and effective. Further clinical trials are underway to assess the long-term safety and results. Cathet Cardiovasc Intervent 2002;56:508–515.Keywords
This publication has 8 references indexed in Scilit:
- Catheter therapy of Swiss cheese ventricular septal defects using the Amplatzer muscular VSD occluderCatheterization and Cardiovascular Interventions, 2002
- Transcatheter closure of single muscular ventricular septal defects using the Amplatzer muscular VSD occluder: Initial results and technical considerationsCatheterization and Cardiovascular Interventions, 2000
- Transcatheter device closure of ventricular septal defects: Immediate results and intermediate-term follow-upAmerican Heart Journal, 1999
- Transcatheter closure of muscular ventricular septal defects with the amplatzer ventricular septal defect occluder: initial clinical applications in children11The Amplatzer VSD occluders were provided by AGA, Medical Corporation, Golden Valley, Minnesota. There were no sources of financial support.Journal of the American College of Cardiology, 1999
- Transcatheter closure of secundum atrial septal defects using the new self-centering amplatzer septal occluder: Initial human experienceCatheterization and Cardiovascular Diagnosis, 1997
- Occlusion of congenital ventricular septal defects by the buttoned device. "Buttoned device" Clinical Trials International Register.Heart, 1997
- Restrictive ventricular septal defect: How small is too small to close?The Annals of Thoracic Surgery, 1993
- Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.Circulation, 1993